| 000 | 01582 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515051409.0 | ||
| 264 | 0 | _c20070205 | |
| 008 | 200702s 0 0 eng d | ||
| 022 | _a1173-2563 | ||
| 024 | 7 |
_a10.2165/00044011-200626080-00003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBernardo, Miguel | |
| 245 | 0 | 0 |
_aCost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. _h[electronic resource] |
| 260 |
_bClinical drug investigation _c2006 |
||
| 300 |
_a447-57 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 |
_aCost-Benefit Analysis _xmethods |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Econometric |
| 650 | 0 | 4 |
_aPiperazines _xadministration & dosage |
| 650 | 0 | 4 |
_aProgram Evaluation _xmethods |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 |
_aSchizophrenia _xeconomics |
| 650 | 0 | 4 | _aSpain |
| 650 | 0 | 4 |
_aThiazoles _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aRamón Azanza, Jose | |
| 700 | 1 | _aRubio-Terrés, Carlos | |
| 700 | 1 | _aRejas, Javier | |
| 773 | 0 |
_tClinical drug investigation _gvol. 26 _gno. 8 _gp. 447-57 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00044011-200626080-00003 _zAvailable from publisher's website |
| 999 |
_c16731851 _d16731851 |
||